Form 8-K - Current report:
SEC Accession No. 0001193125-24-255245
Filing Date
2024-11-12
Accepted
2024-11-12 09:04:29
Documents
14
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d848165d8k.htm   iXBRL 8-K 24752
2 EX-99.1 d848165dex991.htm EX-99.1 69540
  Complete submission text file 0001193125-24-255245.txt   230180

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vinc-20241112.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20241112_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20241112_pre.xml EX-101.PRE 11700
16 EXTRACTED XBRL INSTANCE DOCUMENT d848165d8k_htm.xml XML 3767
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 241443970
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)